Skip to main navigation
Liquidia Logo
Skip to main content
Liquidia Logo

    Home

  • Home

    • About

  • About Liquidia
    • Overview
    • Leadership
    • Board of Directors

    • Products and Pipeline

  • Pipeline and Products
    • Pipeline
    • Commercial Products
    • PRINT® Technology
    • Publications

    • IR Nav

  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Analyst Coverage
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • IR Resources
      • Investor FAQs
      • IR Contact
      • Email Alerts

    • Careers

  • Careers
    • Overview
    • Jobs
    • Benefits
    • Principles

    • Contact Us

  • Contact Us
    • Overview
    • Map/Directions

Event

IR Nav

Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
    Analyst Coverage Stock Quote & Chart Historical Price Lookup Investment Calculator
  • Corporate Governance
    Documents & Charters Leadership Board of Directors Committee Composition
  • SEC Filings
  • IR Resources
    Investor FAQs IR Contact Email Alerts

Wedbush PacGrow Healthcare Conference

Aug 14, 2018 at 9:45 AM EDT

Listen to webcast

Supporting Materials

Wedbush PacGrow Healthcare Conference Presentation 2 MB

IR Tools

  • Print Page
  • Share
  • RSS
Liquidia Logo

PO Box 110085, Research Triangle Park, NC 27709
Tel +1 919-328-4400
Fax +1 919-328-4402

Socials

© 2021 Liquidia, Inc. All Rights Reserved.

Liquidia is a biopharmaceutical company focused on the development and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of pulmonary arterial hypertension (PAH). Our pipeline is focused on the development of two product candidates using our PRINT® Technology platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain.

Our subsidiary, Liquidia PAH (formerly RareGen), generates revenue pursuant to a promotional agreement between RareGen and Sandoz, sharing profit derived from the sale of the first-to-file fully substitutable generic treprostinil injection, or Treprostinil Injection, in the United States.

Legal Nav

  • Legal
  • Privacy
  • Cookies
  • Social Media
  • Facebook
  • Twitter
  • LinkedIn